6.31
price down icon1.56%   -0.10
after-market Dopo l'orario di chiusura: 6.33 0.02 +0.32%
loading
Precedente Chiudi:
$6.41
Aprire:
$6.295
Volume 24 ore:
3.71M
Relative Volume:
0.44
Capitalizzazione di mercato:
$1.17B
Reddito:
$847.25M
Utile/perdita netta:
$-284.86M
Rapporto P/E:
-2.7555
EPS:
-2.29
Flusso di cassa netto:
$-112.35M
1 W Prestazione:
-10.24%
1M Prestazione:
-12.97%
6M Prestazione:
-26.97%
1 anno Prestazione:
-54.93%
Intervallo 1D:
Value
$6.13
$6.34
Intervallo di 1 settimana:
Value
$6.13
$6.99
Portata 52W:
Value
$5.01
$17.81

Novavax Inc Stock (NVAX) Company Profile

Name
Nome
Novavax Inc
Name
Telefono
240-268-2000
Name
Indirizzo
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Name
Dipendente
1,992
Name
Cinguettio
@novavax
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
NVAX's Discussions on Twitter

Confronta NVAX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
NVAX
Novavax Inc
6.31 1.17B 847.25M -284.86M -112.35M -2.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.54 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
511.92 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
313.13 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
540.76 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
257.51 28.51B 3.81B -644.79M -669.77M -6.24

Novavax Inc Stock (NVAX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-28 Iniziato BTIG Research Buy
2024-07-30 Downgrade JP Morgan Neutral → Underweight
2024-05-10 Aggiornamento BofA Securities Underperform → Neutral
2024-05-10 Aggiornamento JP Morgan Underweight → Neutral
2023-08-09 Aggiornamento B. Riley Securities Neutral → Buy
2023-04-20 Downgrade TD Cowen Outperform → Market Perform
2023-03-01 Downgrade B. Riley Securities Buy → Neutral
2023-01-09 Reiterato B. Riley Securities Buy
2022-12-30 Reiterato H.C. Wainwright Buy
2022-12-02 Iniziato Jefferies Hold
2022-09-22 Downgrade JP Morgan Neutral → Underweight
2022-05-20 Iniziato BofA Securities Underperform
2022-02-23 Reiterato B. Riley Securities Buy
2022-02-22 Ripresa Jefferies Buy
2022-01-21 Iniziato Cowen Outperform
2021-05-12 Downgrade JP Morgan Overweight → Neutral
2020-12-14 Iniziato Jefferies Buy
2020-08-06 Reiterato H.C. Wainwright Buy
2020-08-05 Aggiornamento JP Morgan Neutral → Overweight
2020-08-05 Downgrade Ladenburg Thalmann Neutral → Sell
2020-07-16 Reiterato H.C. Wainwright Buy
2020-07-08 Downgrade Ladenburg Thalmann Buy → Neutral
2020-06-29 Reiterato B. Riley FBR Buy
2020-06-29 Reiterato H.C. Wainwright Buy
2020-06-05 Aggiornamento JP Morgan Underweight → Neutral
2020-05-28 Reiterato B. Riley FBR Buy
2020-05-12 Reiterato H.C. Wainwright Buy
2020-04-30 Reiterato H.C. Wainwright Buy
2019-11-27 Ripresa B. Riley FBR Buy
2019-08-14 Reiterato H.C. Wainwright Buy
2019-02-28 Downgrade Piper Jaffray Overweight → Underweight
2018-12-18 Iniziato Ladenburg Thalmann Buy
2018-12-11 Iniziato Oppenheimer Outperform
2018-11-26 Aggiornamento Piper Jaffray Neutral → Overweight
2018-09-21 Aggiornamento JP Morgan Underweight → Overweight
2018-03-29 Aggiornamento Seaport Global Securities Neutral → Buy
Mostra tutto

Novavax Inc Borsa (NVAX) Ultime notizie

pulisher
Jun 17, 2025

Novavax (NVAX): Citi Downgrades to Sell Amid Pipeline Worries - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Novavax stock slips as Citi issues Sell rating (NVAX:NASDAQ) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Insurers likely to cover vaccines without ACIP recommendations - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Novavax (NVAX) Coverage Initiated with 'Sell' Rating by Citigrou - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Novavax (NVAX) Coverage Initiated with 'Sell' Rating by Citigroup | NVAX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Citi initiates Novavax stock with sell rating on strategy shift concerns - Investing.com UK

Jun 17, 2025
pulisher
Jun 17, 2025

Novavax (NVAX) Receives Initial 'Sell' Rating from Citi | NVAX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 13, 2025

Novavax: New Vaccine, Same Old StoryStill A Sell (NASDAQ:NVAX) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 12, 2025

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Novavax: positive results for Covid/flu vaccine - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

Novavax's COVID-Flu Combo Shot Shows Strong Immune Response - Yahoo Finance

Jun 12, 2025
pulisher
Jun 12, 2025

Novavax preps late-stage trial as COVID-flu combo vaccine matches rivals - The Pharma Letter

Jun 12, 2025
pulisher
Jun 12, 2025

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial - Pipelinereview

Jun 12, 2025
pulisher
Jun 12, 2025

RFK Jr. Appoints Vaccine Critics To CDC Vaccine Panel After Firing Entire Advisory Committee: Report - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Novavax at Goldman Sachs Healthcare Conference: Strategic Shift to R&D Focus - Investing.com Nigeria

Jun 12, 2025
pulisher
Jun 11, 2025

RFK Jr. picks eight new members to CDC vaccine advisory panel - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax's COVID-19-Influenza Combination and Stand-alone Influen - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax (NVAX) Phase 3 Trial Shows Promising Results in Vaccine Study | NVAX Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax reports positive results for COVID-19 and flu vaccine candidates By Investing.com - Investing.com South Africa

Jun 11, 2025
pulisher
Jun 11, 2025

Transcript : Novavax, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - marketscreener.com

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax (NasdaqGS:NVAX) Announces Promising Results for New Vaccine Candidates - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial - Benzinga

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax (NVAX) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax's COVID-flu combo vaccine shows strong immune response in trial - Reuters

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax (NVAX) Reports Promising Results for COVID-19-Flu Vaccine Combo - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Tesla, Victoria’s Secret, Novavax rise premarket; Chewy, Gitlab fall By Investing.com - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax's Covid-Influenza Combo, Standalone Flu Vaccines Show 'Robust Immune Responses' in Phase 3 Study - marketscreener.com

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax stock gains on data for COVID-flu shot (NVAX:NASDAQ) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax reports positive results for COVID-19 and flu vaccine candidates - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax (NVAX) Reports Positive Results for COVID-Influenza Comb - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax Reports Promising Phase 3 Vaccine Trial Results - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax (NVAX) Reports Positive Results for COVID-Influenza Combo Vaccine Trial | NVAX Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study - marketscreener.com

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax Breakthrough: Phase 3 Trial Reveals Strong Results for First-of-Kind COVID-Flu Combo Vaccine - Stock Titan

Jun 11, 2025
pulisher
Jun 10, 2025

Vaccine makers steady despite RFK Jr.'s removal of CDC expert panel (PFE:NYSE) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 10, 2025

Vaccine stocks muted as investors assess Kennedy's overhaul of key panel - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Vaccine Stocks Stay Steady Despite US Health Shake-Up - Finimize

Jun 10, 2025
pulisher
Jun 10, 2025

Recombinant Vaccine Market is Booming Worldwide with - openPR.com

Jun 10, 2025
pulisher
Jun 10, 2025

American Pharmacists Association Withholds Endorsement Of CDC's Revised COVID-19 Vaccine Guidance - Benzinga

Jun 10, 2025
pulisher
Jun 09, 2025

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

RFK Jr. removing, replacing all members of CDC vaccine advisory panel (MRNA:NASDAQ) - Seeking Alpha

Jun 09, 2025
pulisher
Jun 09, 2025

Where are the Opportunities in (NVAX) - news.stocktradersdaily.com

Jun 09, 2025
pulisher
Jun 05, 2025

Investor Network: Novavax, Inc to Host Earnings Call - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 05, 2025

July 25th Options Now Available For Novavax (NVAX) - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

LigaChem Biosciences adopts U.S. Novavax technology for next-gen ADCs - Chosunbiz

Jun 05, 2025
pulisher
Jun 02, 2025

Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals - Benzinga

Jun 02, 2025
pulisher
May 31, 2025

Novavax (NVAX) Sees Surge in Bullish Option Activity | NVAX Stoc - GuruFocus

May 31, 2025
pulisher
May 30, 2025

US CDC continues to recommend COVID vaccines for children, contradicts Kennedy - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Novavax (NVAX) Sees Surge in Bullish Option Activity | NVAX Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

RFK Jr. Drops COVID Vaccine Recommendation For Healthy Kids, But Experts Warn Of Major Risks - Benzinga

May 30, 2025
pulisher
May 29, 2025

Novavax to Participate in Upcoming Investor Conferences - Quantisnow

May 29, 2025

Novavax Inc Azioni (NVAX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Novavax Inc Azioni (NVAX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Alton Gregg H
Director
Jun 12 '25
Option Exercise
0.00
10,420
0
28,805
King Rachel K.
Director
Jun 12 '25
Option Exercise
0.00
10,420
0
25,190
Rodgers Richard J
Director
Jun 12 '25
Option Exercise
0.00
10,420
0
24,690
MOTT DAVID M
Director
Jun 12 '25
Option Exercise
0.00
10,420
0
60,890
DOUGLAS RICHARD
Director
Jun 12 '25
Option Exercise
0.00
10,420
0
54,340
$20.68
price down icon 2.27%
$35.40
price up icon 1.55%
$20.39
price down icon 0.83%
$105.42
price up icon 2.67%
$103.01
price down icon 3.30%
biotechnology ONC
$257.51
price up icon 4.22%
Capitalizzazione:     |  Volume (24 ore):